Publicaciones en colaboración con investigadores/as de German Center for Neurodegenerative Diseases (14)

2024

  1. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

2022

  1. Correction to: EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3 (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 2, (632-651), 10.1007/s00259-021-05603-w)

    European Journal of Nuclear Medicine and Molecular Imaging

  2. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 2, pp. 632-651

2021

  1. Finding our way through the labyrinth of dementia biomarkers

    European Journal of Nuclear Medicine and Molecular Imaging

2020

  1. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962

  2. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 8, pp. 1885-1912

  3. Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

    European Journal of Nuclear Medicine and Molecular Imaging

2018

  1. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217

  2. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1557-1566

  3. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1534-1545

  4. Clinical utility of FDG-PET for the clinical diagnosis in MCI

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1497-1508

  5. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1546-1556

  6. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1487-1496

  7. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1526-1533